A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma


Study Number
521819
Phase
1b/2
Purpose

This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.

Full Title

A Phase 1b/2, Open-Label, Study of Tivozanib in Combination with
Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma

ClinicalTrials.Gov ID
NCT03970616

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.